Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968546616> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W1968546616 endingPage "31S" @default.
- W1968546616 startingPage "25S" @default.
- W1968546616 abstract "Dabigatran etexilate, an oral direct thrombin inhibitor, was investigated in 3 large phase III trials for the prevention of venous thromboembolism (VTE) after total hip arthroplasty (RE-NOVATE, N = 3494) or total knee arthroplasty (RE-MODEL, N = 2076 and RE-MOBILIZE, N = 2615). RE-NOVATE and RE-MODEL were conducted mainly in Europe, and RE-MOBILIZE was conducted predominantly in the United States and Canada. This review discusses the results of these trials. In all 3 trials, 2 doses, 220 mg and 150 mg once daily, were compared with enoxaparin. Both RE-MODEL and RE-NOVATE demonstrated noninferiority for the primary outcome (a composite of total VTE events and all-cause mortality), P = .0003 and P < .0001, respectively, for these trials. In 2008, these data formed the basis for European and Canadian approval. While RE-MOBILIZE did not demonstrate noninferiority for the primary outcome (25.3% for enoxaparin vs 31.1% for 220 mg, risk difference +5.8%, 95% CI, 0.8-10.8; P = .02 and 33.7% for 150 mg, risk difference +8.4%, 95% CI, 3.4-13.3; P = .0009), both treatments were similar for the secondary composite outcome (major VTE plus VTErelated mortality; 3.4% with 220 mg, 3.0% with 150 mg, and 2.2% with enoxaparin) and symptomatic deep vein thrombosis (0.8%, 0.7%, and 0.6%). There were no differences in the bleeding rates, hepatic enzyme elevations, or acute coronary syndrome events between the 2 treatments. With the practical advantages of once-daily oral dosing, dabigatran etexilate can be considered an attractive alternative to conventional thromboprophylaxis regimens in patients undergoing elective total hip and knee arthroplasty." @default.
- W1968546616 created "2016-06-24" @default.
- W1968546616 creator A5002245039 @default.
- W1968546616 creator A5083647812 @default.
- W1968546616 date "2009-02-01" @default.
- W1968546616 modified "2023-09-27" @default.
- W1968546616 title "Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty" @default.
- W1968546616 cites W1531871815 @default.
- W1968546616 cites W2000438765 @default.
- W1968546616 cites W2019561783 @default.
- W1968546616 cites W2022932023 @default.
- W1968546616 cites W2031581415 @default.
- W1968546616 cites W2035193897 @default.
- W1968546616 cites W2053934599 @default.
- W1968546616 cites W2115348966 @default.
- W1968546616 cites W2165506983 @default.
- W1968546616 cites W2441750859 @default.
- W1968546616 cites W2586494451 @default.
- W1968546616 cites W2980049052 @default.
- W1968546616 doi "https://doi.org/10.1177/1076029609340668" @default.
- W1968546616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19648146" @default.
- W1968546616 hasPublicationYear "2009" @default.
- W1968546616 type Work @default.
- W1968546616 sameAs 1968546616 @default.
- W1968546616 citedByCount "18" @default.
- W1968546616 countsByYear W19685466162012 @default.
- W1968546616 countsByYear W19685466162013 @default.
- W1968546616 countsByYear W19685466162014 @default.
- W1968546616 crossrefType "journal-article" @default.
- W1968546616 hasAuthorship W1968546616A5002245039 @default.
- W1968546616 hasAuthorship W1968546616A5083647812 @default.
- W1968546616 hasConcept C126322002 @default.
- W1968546616 hasConcept C141071460 @default.
- W1968546616 hasConcept C2776301958 @default.
- W1968546616 hasConcept C2776710957 @default.
- W1968546616 hasConcept C2777288759 @default.
- W1968546616 hasConcept C2778336525 @default.
- W1968546616 hasConcept C2778810321 @default.
- W1968546616 hasConcept C2778959117 @default.
- W1968546616 hasConcept C2779161974 @default.
- W1968546616 hasConcept C2780011451 @default.
- W1968546616 hasConcept C2780868729 @default.
- W1968546616 hasConcept C2991741193 @default.
- W1968546616 hasConcept C71924100 @default.
- W1968546616 hasConceptScore W1968546616C126322002 @default.
- W1968546616 hasConceptScore W1968546616C141071460 @default.
- W1968546616 hasConceptScore W1968546616C2776301958 @default.
- W1968546616 hasConceptScore W1968546616C2776710957 @default.
- W1968546616 hasConceptScore W1968546616C2777288759 @default.
- W1968546616 hasConceptScore W1968546616C2778336525 @default.
- W1968546616 hasConceptScore W1968546616C2778810321 @default.
- W1968546616 hasConceptScore W1968546616C2778959117 @default.
- W1968546616 hasConceptScore W1968546616C2779161974 @default.
- W1968546616 hasConceptScore W1968546616C2780011451 @default.
- W1968546616 hasConceptScore W1968546616C2780868729 @default.
- W1968546616 hasConceptScore W1968546616C2991741193 @default.
- W1968546616 hasConceptScore W1968546616C71924100 @default.
- W1968546616 hasIssue "1_suppl" @default.
- W1968546616 hasLocation W19685466161 @default.
- W1968546616 hasLocation W19685466162 @default.
- W1968546616 hasOpenAccess W1968546616 @default.
- W1968546616 hasPrimaryLocation W19685466161 @default.
- W1968546616 hasRelatedWork W1982878874 @default.
- W1968546616 hasRelatedWork W2010347505 @default.
- W1968546616 hasRelatedWork W2084295818 @default.
- W1968546616 hasRelatedWork W2327402414 @default.
- W1968546616 hasRelatedWork W2365903619 @default.
- W1968546616 hasRelatedWork W2440439573 @default.
- W1968546616 hasRelatedWork W2801779377 @default.
- W1968546616 hasRelatedWork W2900286332 @default.
- W1968546616 hasRelatedWork W2981730791 @default.
- W1968546616 hasRelatedWork W4313554662 @default.
- W1968546616 hasVolume "15" @default.
- W1968546616 isParatext "false" @default.
- W1968546616 isRetracted "false" @default.
- W1968546616 magId "1968546616" @default.
- W1968546616 workType "article" @default.